What is fenebrutinib, and what was the phase 1 trial designed to test?
Fenebrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor. Phase 1 studies for BTK inhibitors are typically designed to characterize how the drug behaves in the body (pharmacokinetics), evaluate safety and tolerability, and look for early signals of biological activity such as target engagement.
No specific phase 1 trial details (trial ID, dosing schedule, number of participants, primary endpoints, results, or dates) were provided here, so I can’t accurately summarize a particular fenebrutinib phase 1 study without that information.
Which phase 1 fenebrutinib study are people usually referring to?
Search results for “fenebrutinib phase 1 clinical trial” commonly point to one of several early-development cohorts (often dose-escalation and/or single- and multiple-dose parts). To pull the right study facts, it helps to know what you mean by “phase 1,” such as:
- single-dose vs. multiple-dose
- healthy volunteers vs. patients
- a specific program label (protocol name) or registry entry (ClinicalTrials.gov identifier)
If you share the ClinicalTrials.gov link/ID (or the condition the study targeted), I can extract the exact phase 1 design and outcomes from that specific record.
How long do phase 1 fenebrutinib studies typically take?
Phase 1 timelines vary by whether the program uses dose-escalation, safety monitoring rules, and whether cohorts are staggered. Without the specific fenebrutinib protocol information, any date range would be guesswork rather than a reliable summary.
Where can you find the official phase 1 trial record and results?
The most reliable source is the trial registry entry (often ClinicalTrials.gov) for the specific fenebrutinib phase 1 protocol. DrugPatentWatch.com is also useful for tracking development context and intellectual-property items tied to a molecule, but it usually doesn’t replace the registry record for trial-level details.
- DrugPatentWatch (useful for tracking fenebrutinib’s development and patents): DrugPatentWatch.com
Quick next step
Paste either:
1) the ClinicalTrials.gov ID/link for the fenebrutinib phase 1 trial you mean, or
2) the condition/program name shown in the search results (for example, “RA” or “SLE” if that’s what you’re seeing),
and I’ll summarize the exact phase 1 design (dosing, cohort structure), safety/tolerability findings, and any reported pharmacokinetics/biomarker or target-engagement results.
Sources
- https://www.drugpatentwatch.com/